Latest | Instant Finance & Market News_第201页 | NewTimeSpace

09:07

[ TSAKER NE (01986.HK): Proposes establishment of joint venture with Zijin Lithium to develop iron phosphate business, with registered capital of RMB 93.2 million ] NewTimeSpace News: TSAKER NE (01986.HK): Shandong Tsaker New Materials, an indirect non-wholly-owned subsidiary, entered into a joint venture agreement with Zijin Lithium to establish a joint venture with a registered capital of RMB 93.2 million for the iron phosphate business, with the Group side holding 55%; the transaction constitutes a discloseable transaction exempt from the circular and shareholders' approval requirements.

Tag： TSAKER NE 01986.HK

09:04

[ JIANGXI BANK (01916.HK): Proposes private placement of up to 715,000,000 domestic shares and 215,000,000 H shares under specific mandate; net proceeds to replenish core Tier 1 capital ] NewTimeSpace News: JIANGXI BANK (01916.HK): The Board proposes to privately place up to 715,000,000 domestic shares and 215,000,000 H shares under a specific mandate, with the net proceeds used in full to replenish core Tier 1 capital; the domestic share issuance targets up to 35 domestic institutional investors, the H share issue price will not be lower than the benchmark price, and an EGM and class meetings will be convened to seek approval.

Tag： JIANGXI BANK 01916.HK Issuance

09:01

[ MINTH GROUP (00425.HK): Groundbreaking ceremony held for new production plant in Alabama, US; planned phased investment of approximately USD 430 million ] NewTimeSpace News: MINTH GROUP (00425.HK): The Group held a groundbreaking ceremony for its new production plant in Gadsden, Alabama, US, with planned phased investment of approximately USD 430 million; first-phase capacity is expected to commence production in 2027, and upon completion the plant will create more than 1,300 jobs and become the Group's largest site globally.

Tag： MINTH GROUP 00425.HK Overseas Plant Construction

08:58

[ CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma ] NewTimeSpace News: CARSGEN-B (02171.HK): The universal CAR-T product CT1190B targeting CD19/CD20 has received IND approval from the NMPA for the treatment of patients with R/R LBCL who have failed at least two lines of standard therapy; the product was developed on the THANK-u Plus platform, with IIT results presented as a poster at the 2026 EHA annual meeting.

Tag： CARSGEN-B 02171.HK R&D Progress

08:05

[ IMMUNEONCO-B (01541.HK): Subsidiary Yiming Kaier receives RMB 50 million capital increase from Shengke Qihang and other investors; Company to hold approximately 68.34% upon completion ] NewTimeSpace News: IMMUNEONCO-B (01541.HK): The Company's non-wholly-owned subsidiary Yiming Kaier received a capital increase of RMB 50 million in total consideration from investors including Shengke Qihang, Xinjie Chuangyuan and Mr. Wang Xueyan, with the investors subscribing for approximately 15.83% of the enlarged equity; upon completion the Company will hold approximately 68.34%, the target company will remain a non-wholly-owned subsidiary, and the transaction is fully exempt from Chapter 14 of the Listing Rules.

Tag： IMMUNEONCO-B 01541.HK

08:03

[ CHK OIL (00632.HK): Resignation of CFO, company secretary, authorised representative and process agent; non-compliance with Listing Rules ] NewTimeSpace News: CHK OIL (00632.HK): Mr. Zheng Zhensheng has resigned as CFO, company secretary, authorised representative and process agent with effect from 7 August 2026; following the resignation the Company is temporarily not in compliance with Rules 3.05, 3.28 and 19.05(2) of the Listing Rules relating to authorised representatives, company secretary and process agent, and is seeking candidates to fill the vacancies as soon as practicable.

Tag： CHK OIL 00632.HK

08:00

[ TONTINE WINES (00389.HK): Substantial shareholder Wang He initiates court proceedings in the High Court over placing agreement; Company to actively defend ] NewTimeSpace News: TONTINE WINES (00389.HK): The Company received notice of court proceedings commenced by Shuntuo Development Limited and Mr. Wang He in the High Court of Hong Kong (Miscellaneous Proceedings No. 1316 of 2026) over the placing agreement, seeking declarations that the agreement is void and injunctions; the Company intends to actively defend, and the Board considers the proceedings have no immediate material adverse impact on the Group's existing business operations or financial position.

Tag： TONTINE WINES 00389.HK

07:57

[ TRANSCENTA-B (06628.HK): Proposes disposal of CDMO assets for RMB 190 million to a WuXi Biologics subsidiary, focusing on innovative drug R&D as core business ] NewTimeSpace News: TRANSCENTA-B (06628.HK): The Company's wholly-owned subsidiary proposes to dispose of its CDMO assets to a wholly-owned subsidiary of WuXi Biologics for RMB 190 million, with an estimated loss of approximately RMB 280 million to be recognised; the transaction constitutes a major transaction subject to shareholders' approval, with the circular expected to be despatched on or before 25 August 2026.

Tag： TRANSCENTA-B 06628.HK

07:54

[ OCT (ASIA) (03366.HK): Proposes disposal of 100% equity interest in OCT (Huizhou) via public listing for RMB 306,732,900; EGM to be held on 21 August ] NewTimeSpace News: OCT (ASIA) (03366.HK): The Company proposes to dispose of the 100% equity interest in OCT (Huizhou) Industrial Park Management Co., Ltd. through a public listing for a final consideration of RMB 306,732,900, with Shenghong Technology (Huizhou) Co., Ltd. as the purchaser; the target property was valued at approximately RMB 280 million, representing an appreciation of approximately RMB 154 million over book value; an EGM will be held on 21 August 2026.

Tag： OCT (ASIA)03366.HK

07:34

[ CCTC(06951.HK) will spend CNY 159.56 million to repurchase 1.29 million shares on Aug 6, 2026 ] CCTC(06951.HK) will spend CNY 159.56 million to repurchase 1.29 million shares on Aug 6, 2026 .

Tag： CCTC 06951.HK

22:07

[ DRAGON MINING (01712.HK): New Holding Company Lung Kam Resources to List on HKEX Main Board by Introduction; Dragon Mining to Withdraw Listing ] NewTimeSpace News: DRAGON MINING announced that its wholly-owned subsidiary Lung Kam Resources will list on the HKEX Main Board by way of introduction, with each scheme share exchanged for one New Holding Company share and the Company's listing withdrawn upon completion; dealings in the New Holding Company shares are expected to commence on 2 September 2026 under the existing code 1712 with the short name "Dragon Mining" and a board lot of 1,000 shares; the scheme remains subject to court approval.

Tag： DRAGON MINING 01712.HK Product Launch

21:55

[ TRANSTHERA-B (02617.HK): Class 1 New Drug Jientai (Tiengotinib Tablets) Receives Conditional NMPA Approval for FGFR2 Fusion Advanced Cholangiocarcinoma ] NewTimeSpace News: TRANSTHERA-B announced that its self-developed Class 1 new drug Jientai (tiengotinib tablets) has received conditional NMPA approval for marketing, for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements in patients previously treated with systemic therapy and FGFR inhibitors; the Phase II pivotal study showed an ORR of 28.0% and median overall survival of 20.7 months; the drug has received US FDA Orphan Drug Designation and Fast Track Designation and European EMA Orphan Drug Designation, and this is its first indication approved in China.

Tag： TRANSTHERA-B 02617.HK NMPA Approval

21:47

[ TOP EDUCATION (01752.HK): Acknowledges Potential Data Security Incident, Launches Investigation and Notifies Regulators ] NewTimeSpace News: TOP EDUCATION announced that on 5 August it became aware of a threat actor claiming to possess and intend to sell records allegedly relating to students on an underground forum; the Group has immediately launched an investigation and notified the Tertiary Education Quality and Standards Agency and the Australian Cyber Security Centre; the suspected incident has not caused material disruption to the Group's operations to date, and the Group will take appropriate actions as the investigation progresses.

Tag： TOP EDUCATION 01752.HK network security

21:34

[ HENGRUI PHARMA (01276.HK): Trastuzumab Rezetecan Approved for Third Indication, Becoming China's First Anti-HER2 Product Approved for Colorectal Cancer ] NewTimeSpace News: HENGRUI PHARMA announced that the third indication of its subsidiary Suzhou Shengdiya's trastuzumab rezetecan for injection has been approved for marketing, for adult patients with HER2-positive colorectal cancer who failed oxaliplatin, fluorouracil and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China; the self-developed HER2 ADC has its pivotal Phase III data presented at the 2026 ASCO Annual Meeting, 11 indications included in the Breakthrough Therapy Designation list, and cumulative R&D investment of approximately RMB 2.144 billion.

Tag： HENGRUI PHARMA 01276.HK Indications approved

21:28

[ HENGRUI PHARMA (01276.HK): Class 1 Innovative Drug Ivarmacitinib Sulfate Tablets Approved for Fifth Indication, Completing Full-Disease-Spectrum Coverage of Axial Spondyloarthritis ] NewTimeSpace News: HENGRUI PHARMA announced that the NMPA has approved a fifth indication for its self-developed Class 1 innovative drug ivarmacitinib sulfate tablets, for adult patients with active non-radiographic axial spondyloarthritis, achieving full-disease-spectrum oral targeted management coverage of axial spondyloarthritis; the product is a highly selective JAK1 inhibitor with pivotal Phase III data presented at the 2026 EULAR Annual Meeting, and cumulative R&D investment of approximately RMB 1.235 billion.

Tag： HENGRUI PHARMA 01276.HK biopharmaceutical

21:17

[ ENVISION GREEN (01783.HK): Subsidiary to Purchase High-Performance Servers for RMB 1.2884 Billion, Constituting a Major Transaction ] NewTimeSpace News: ENVISION GREEN announced that its indirect wholly-owned subsidiary Shanghai Youfu Cloud Computing intends to purchase high-performance servers for RMB 1.2884 billion (approximately HKD 1.4885 billion, inclusive of tax) from Shanghai Shunquan Technology to support the Group's cloud computing and intelligent computing capabilities; as the applicable percentage ratios exceed 25% but are below 100%, the transaction constitutes a major transaction; written approval from shareholders holding approximately 50.62% has been obtained, and no general meeting will be convened.

Tag： ENVISION GREEN 01783.HK Business Updates

20:03

[ NETJOY (02131.HK): Independent Internal Control Follow-up Review Completed with All Remedial Measures Implemented; Trading Suspension Continues ] NewTimeSpace News: NETJOY announced that its independent internal control follow-up review has been completed; all remedial measures recommended in the internal control review report have been implemented and are operating, except for procurement acceptance processes (not applicable as the Group ended its new short-drama purchase business in June) and inventory transfers (no samples available as the Group operates a single warehouse), with the Board affirming the rectification results; the Company's shares have been suspended since 1 April 2025 and will remain suspended until all resumption guidance is met.

Tag： Netjoy 02131.HK internal control review

19:50

[ Sichuan Biokin Pharmaceutical Files for Hong Kong IPO: Yizekang Becomes World's First Approved Bispecific ADC with 15 Clinical-Stage Pipeline Candidates ] NewTimeSpace News: Sichuan Biokin Pharmaceutical filed for a Hong Kong IPO on 6 August with CITIC Securities, Jefferies, CICC and Deutsche Bank as joint sponsors; the integrated biopharmaceutical group has 15 clinical-stage candidates, five of which are in overseas clinical development; core product Yizekang is the world's first approved bispecific ADC with NDAs approved by the NMPA for nasopharyngeal carcinoma and esophageal squamous cell carcinoma, while T-Bren is a HER2 ADC with best-in-class potential.

Tag： Biokin Pharma IPO file a listing application

19:35

[ PACIFIC BASIN(02343.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 105.05 million, YoY increase of 310.35% ] NewTimeSpace News: August 06, 2026, PACIFIC BASIN(02343.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.11 billion, increased by 8.52% YoY.

Tag： PACIFIC BASIN 02343.HK profit growth

19:33

[ TOM GROUP(02383.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of HKD 157.44 million, loss widened by 59.51% YoY ] NewTimeSpace News: August 06, 2026, TOM GROUP(02383.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 335.25 million, decreased by 1.02% YoY.

Tag： TOM GROUP 02383.HK Loss widens

Scan QR Code

Download App